Richard C. Young & CO. LTD. cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,633 shares of the company’s stock after selling 252 shares during the quarter. Johnson & Johnson comprises approximately 2.7% of Richard C. Young & CO. LTD.’s investment portfolio, making the stock its 6th biggest position. Richard C. Young & CO. LTD.’s holdings in Johnson & Johnson were worth $20,073,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P lifted its holdings in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its position in shares of Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. increased its holdings in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd raised its position in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $154.41 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The firm’s 50 day moving average is $159.89 and its two-hundred day moving average is $165.86. The firm has a market capitalization of $401.27 billion, a P/E ratio of 32.30, a P/E/G ratio of 2.67 and a beta of 0.53.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 3.08%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is currently 99.58%.
Insider Transactions at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on JNJ. Atlantic Securities dropped their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Piper Sandler cut their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Guggenheim began coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.